Development of Magnetic Resonance Spectroscopy Techniques for Imaging Metabolites and Neurotransmitters in Human Brain

This study is currently recruiting participants.
Verified July 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01266577
First received: December 23, 2010
Last updated: March 14, 2014
Last verified: July 2013

December 23, 2010
March 14, 2014
December 2010
Not Provided
The primary outcome is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR) ratio, spectral lineshape, linewidth, and resolution.
Not Provided
Complete list of historical versions of study NCT01266577 on ClinicalTrials.gov Archive Site
The secondary outcome is the performance improvements of the scanner hardware, software and methodology.
Not Provided
Not Provided
Not Provided
 
Development of Magnetic Resonance Spectroscopy Techniques for Imaging Metabolites and Neurotransmitters in Human Brain
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites and Neurotransmitters in Human Brain

Background:

- Magnetic resonance imaging (MRI) is a widely used scanning technique to obtain images of the human body and evaluate activity in the brain. A particular MRI method called magnetic resonance spectroscopy (MRS) can be used to study brain chemistry as well, which may help researchers who are studying new treatments for psychiatric illnesses. Researchers are interested in improving current MRI and MRS techniques, as well as developing new MRI and MRS techniques to view and measure brain chemicals and brain activity.

Objectives:

- To implement, develop, and optimize brain chemistry imaging techniques using magnetic resonance imaging and magnetic resonance spectroscopy.

Eligibility:

- Healthy individuals between 18 and 65 years of age.

Design:

  • This study will involve a screening visit and a scanning visit at the National Institutes of Health Clinical Center.
  • Participants will be screened with a full medical and physical examination, blood and urine tests, and neurological testing.
  • During the second visit, participants will have an MRI scan of the brain. (Participants who have received an MRI within the past year will not need to have a second one; the images of the previous scan will be used for this study.) All participants will then have an MRS scan using the same scanning equipment.

Magnetic resonance spectroscopy (MRS) is identical to MRI except that the metabolite signal, rather than the dominant water signal, is measured. By using water suppression techniques, MRS can monitor levels of important brain metabolites and neurotransmitters such as N-acetylaspartate (NAA), creatine, choline, lactate, myo-inositol, and glutamate/glutamine. Gamma aminobutyric acid (GABA) (the major inhibitory neurotransmitter in the brain) and glutathione (an important marker of oxidative stress and aging) are overlapped spectrally by other more intense metabolites such as creatine. Thus, spectral editing techniques are needed to reveal GABA and glutathione in the proton MRS spectra.

This protocol proposes two main goals. First, to implement and optimize current MRS methods published in the literature for the imaging of GABA and glutathione. Second, to further develop new methods for use in similar brain MRS applications.

To develop and optimize in vivo MRS methods, 150 healthy volunteers will be recruited over a period of three years. The subjects will be aged 18-65 years, and include representative numbers of males, females, and minorities.

The experiments will be performed on the GE 3T Siemens 3T and 7T MRI scanners located at the NIH In Vivo NMR Research Center. In the first portion of the study, a clinical MRI will be performed to ensure the subject has no abnormal brain conditions. In the second portion of the study, MRS scans will be performed in various system and pulse parameter combinations. No medications will be involved. Total scan time during the MRS scan will be one to two hours long.

We expect to obtain high quality GABA and glutathione spectroscopy imaging from healthy volunteers that will help establish accurate and reliable spectroscopy methods for clinical investigators to perform non-invasive studies of psychiatric and neurological disorders.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Brain Mapping
  • Healthy Volunteer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
Not Provided
Not Provided
  • INCLUSION CRITERIA:
  • 18-65 years of age
  • in good health, as indicated by the medical evaluation and screening at the NIH

EXCLUSION CRITERIA:

  • have been diagnosed or treated for any psychiatric illness in the last 90 days
  • history of drug abuse in the last 90 days, being defined as any use of an illicit substance, or use of a prescription or over the counter medication for reasons or in amounts, other than instructed use. (caffeine and nicotine are not exclusionary)
  • in the last 90 days, have history of alcohol abuse or dependence, or have more than moderate alcohol consumption defined as a daily average of four or more ounces for men or three or more ounces for women. (one ounce being considered to be equal to one beer, one glass of wine or one mixed drink)
  • serious medical illness likely to modify brain anatomy and/or physiology, such as heart disease, liver disease, hypertension, kidney disease, diabetes, or a seizure disorder.
  • claustrophobic inside the MRI scanner
  • metallic (ferromagnetic) implants, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, shrapnel fragments, and possible small metal fragments in the eye
  • unable to lie flat on back for up to 2 hours
  • past brain surgery
  • pregnant
  • unable or unwilling to sign an informed consent document
Both
18 Years to 65 Years
Yes
Contact: Christopher Johnson (301) 402-6695 johnsonchri@mail.nih.gov
Contact: Shizhe Steve Li, Ph.D. (301) 435-8859 steveli@mail.nih.gov
United States
 
NCT01266577
110045, 11-M-0045
Not Provided
Not Provided
National Institute of Mental Health (NIMH)
Not Provided
Principal Investigator: Shizhe Steve Li, Ph.D. National Institute of Mental Health (NIMH)
National Institutes of Health Clinical Center (CC)
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP